Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.74 |
| ▸ | PDE2A | O00408 | 4/20 | 0.72 |
| ▸ | PDE8A | O60658 | 4/20 | 0.72 |
| ▸ | PDE5A | O76074 | 4/20 | 0.72 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.72 |
| ▸ | PDE11A | Q9HCR9 | 4/20 | 0.72 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.72 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.72 |
| ▸ | PDE9A | O76083 | 3/20 | 0.72 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.72 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.72 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18380631 | 0.93 | PDE4A (0.85) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL23082925 | 0.92 | PDE4A (0.88) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL8060473 | 0.92 | PDE4A (0.88) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL10201379 | 0.89 | PDE4A (0.69) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL21182694 | 0.88 | PDE4A (0.84) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL17508454 | 0.88 | PDE4A (0.84) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL19217069 | 0.87 | PDE4A (0.81) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL18211963 | 0.85 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL18771113 | 0.85 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL16324627 | 0.85 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170128453-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-9545406-B2 | Method of treating a CNS injury with a PDE1 inhibitor | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160375028-A1 | ORGANIC COMPOUNDS | FIENBERG ALLEN A (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9403836-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140357606-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2014-12-04 | — | — | US | disclosed |
| US-8829008-B2 | Organic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20120238589-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE4A 2/4885PDE2A 4/4885PDE8A 264/4885 |
| US-20170128453-A1 | NOVEL USES | BDNF, CNTN1, DCX | PDE4A 27/4885PDE2A 14/4885PDE8A 215/4885 |
| US-20140357606-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | PDE4A 734/4885PDE2A 358/4885PDE8A 1400/4885 |
| US-10010553-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE4A 2/4885PDE2A 4/4885PDE8A 264/4885 |
| US-20160375028-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE4A 2/4885PDE2A 4/4885PDE8A 264/4885 |
| US-20120238589-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | PDE4A 734/4885PDE2A 358/4885PDE8A 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.